Gene Editing May Hold the Key to Curing Sickle Cell Disease
March 21, 2023
Source: drugdu
126
Researchers from the University of California, Berkeley have used CRISPR gene-editing technology to cure sickle cell disease in mice. Sickle cell disease is a genetic blood disorder that affects millions of people worldwide. The disease is caused by a mutation in the HBB gene, which produces an abnormal form of hemoglobin that causes red blood cells to become misshapen and break down easily.
Using CRISPR, the researchers were able to correct the HBB gene in mice with sickle cell disease. The corrected gene produced normal hemoglobin, which prevented the misshapen red blood cells from forming. The mice were cured of the disease and showed no signs of sickle cell-related symptoms.
The researchers say that the same approach could be used to cure sickle cell disease in humans. While more research is needed before clinical trials can begin, this is a promising development in the field of gene therapy.
Reference: https://news.harvard.edu/gazette/story/2021/06/gene-editing-shows-promise-as-sickle-cell-therapy/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
